Objective To observe the clinical efficacy of Qishen Yiqi Dropping Pills combined with telmisartan on early diabetic nephropathy with Qi deficiency and blood stasis syndrome and changes of oxidative stress indicators. Methods Sixty patients with early diabetic nephropathy of qi-yin deficiency and blood stasis syndrome were randomly divided into treatment group (30 cases) and control group (30 cases). Both groups were given diabetes education, diabetes diet control and insulin injection. Patients in the control group took telmisartan orally, and patients in the treatment group were given Qishen Yiqi Dropping Pills additionally. The treatment course was 12 weeks. The indicators were observed before and after treatment including blood pressure (BP), fasting blood glucose (FBG), glycated hemoglobin (HbA1c), urinary albumin excretion rate (UAER), urinary 8-iso-PGF2α excretion rate, serum superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and malonaldehyde (MDA), and the clinical efficacy was evaluated. Results The total effective rate of the treatment group was significantly higher than that of the control group, with statistical significance (Z=2.822, P=0.005). After treatment, the indicators including BP, FBG, HbA1c, serum MDA, UAER and urinary 8-iso-PGF2α excretion rate all decreased significantly in both groups (P<0.05). Serum SOD and GSH-Px increased significantly at the same time (P<0.05). BP, FBG and HbA1c were not statistically different between the two groups (P>0.05). However, serum MDA, UAER, and urinary 8-iso-PGF2αexcretion rate were significantly lower (P<0.05), and serum SOD and GSH-Px were significantly higher in treatment group than control group (P<0.05). Conclusion Qishen Yiqi Dropping Pill combined with telmisartan is effective in reducing proteinuria in patients with early diabetic nephropathy of qi-yin deficiency and blood stasis syndrome. Its protective mechanism for kidney is possibly related to inhibiting oxidative stress injury at the early stage of diabetic nephropathy.

OBJECTIVE:To establish RP-HPLC combined with solid phase extraction method to determine the plasma concentration of lansoprazole.METHODS:The sample was extracted by solid phase extraction in darkness.RP-HPLC was applied using Venusil XBP-C18(200 mm?4.6 mm,5 ?m) column.The mobile phase consisted of acetonitrile-water(32:68,pH value adjusted to 7.6 with 1% ammonia water) and flow rate was 1.0 mL?min-1.The detection wavelength was set at 284 nm and column temperature was set at room temperature.RESULTS:The linear range of lansoprazole was 10～2 500 ng?mL-1(r=0.999 9) with mean recovery of 100.93%.The RSD of intra-day and inter-day were both less than 10%.CONCLUSION:The method is sensitive,convenient and rapid for the determination of lansoprazole concentration in plasma.

Aged ; Ambulances ; statistics & numerical data ; Angioplasty, Balloon, Coronary ; Emergency Service, Hospital ; statistics & numerical data ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; therapy ; Prospective Studies ; Time Factors ; Treatment Outcome

A field transfusion device without support is designed.It is in shape of cuboid,and the idler wheels of mean axis disc are driven by motor to push transfusion liquid into human body.A disc with 6 idler wheels on the edge is set in the motor axis.When motor starts,idler wheels take turns to extrude liquid from transfusion pipe to human body with transfusion speed decided by motor rotate speed.Besides,an adjustable transfusion controller,sensor for liquid pressure and transfusion alarm system are equipped.When the set transfusion volume is finished,it gives alarm.

AIM: To evaluate the effect of EffecteneTM lipofectine mediated plasmids encoding human pcDNA4-vascular endothelia growth inhibitor (pcDNA4-VEGI) gene on corneal neovascularization (CNV).METHODS: Forty New Zealand albino rabbits were sutured by 5- 0 silk on the superior cornea to induce CNV and divided into 4 random teams, ten per each team: team A: transfected by pcDNA4-VEGI gene mediated by EffecteneTM lipofectine transfection; team B: by plasmid pcDNA4; team C: by EffecteneTM, and team D: by normal saline. Length and area of CNV were observed under slit lamp every day after transfection. Immunohistochemistry was performed to detect the expression of VEGI protein in corneas at day 3, 7, 14 and 21. RESULTS: 1) Average occurrence of CNV was 6.3 days in team A, 3.1 days in team B, 3.2 days in team C, and 3.2 days in team D. Difference was significant between A and other teams (P<0.01); 2) Length and average area of CNV in each period in team A was significantly different from those in team B, C and D (P<0.01); 3) VEGI expressions were observed in epithelium, stroma, endothelium and the cliff of CNV in team A at 3 days after transfection by immunohistochemical staining. None VEGI positive cells were found in the control teams (team B, C and D) all the time.CONCLUSION: EffecteneTM lipofectine transfection technique can effectively transfect pcDNA4-VEGI gene into rabbit cornea and the length and CNV areas can be inhibited by VEGI gene.

Acute Coronary Syndrome ; drug therapy ; Anticoagulants ; therapeutic use ; Humans ; Polysaccharides ; therapeutic use

Athletes ; Humans ; Microcirculation ; Muscles ; physiology ; Sports

Humans ; Platelet Aggregation Inhibitors ; therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex ; antagonists & inhibitors

Adult ; Brugada Syndrome ; complications ; physiopathology ; Bundle-Branch Block ; Electrocardiography ; Humans ; Male

Autophagy ; Humans ; Myocardial Reperfusion Injury